Chemotherapy-Free Intervals in Management of Metastatic Colorectal Cancer
EP. 2: First-Line Options in mCRC
Axel Grothey, MD, West Cancer Center & Research Institute
Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.
EP. 3: Optimizing First-Line Therapy in mCRC
Axel Grothey, MD, West Cancer Center & Research Institute
Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.
EP. 4: Maintenance or Chemo-Free Interval in mCRC
Axel Grothey, MD, West Cancer Center & Research Institute
Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.
EP. 6: Regorafenib in Third or Fourth Line for mCRC: Efficacy in the Re-DOS Trial
Axel Grothey, MD, West Cancer Center & Research Institute
John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.
EP. 7: Regorafenib in Third or Fourth Line for mCRC: Safety in the Re-DOS Trial
Axel Grothey, MD, West Cancer Center & Research Institute
Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.
EP. 8: TAS-102 in Third or Fourth Line for mCRC
Axel Grothey, MD, West Cancer Center & Research Institute
Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.
EP. 9: Using Molecular Testing to Guide Treatment Selection in mCRC
Axel Grothey, MD, West Cancer Center & Research Institute
John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.
